tetano
Editor, Senior Moderator
Adv Drug Deliv Rev
. 2020 Dec 16;169:137-151.
doi: 10.1016/j.addr.2020.12.008. Online ahead of print.
Non-viral COVID-19 vaccine delivery systems
Kyung Soo Park[SUP] 1 [/SUP], Xiaoqi Sun[SUP] 2 [/SUP], Marisa E Aikins[SUP] 2 [/SUP], James J Moon[SUP] 3 [/SUP]
Affiliations
Abstract
The novel corona virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the globe at a formidable speed, causing tens of millions of cases and more than one million deaths in less than a year of its report in December 2019. Since then, companies and research institutions have raced to develop SARS-CoV-2 vaccines, ranging from conventional viral and protein-based vaccines to those that are more cutting edge, including DNA- and mRNA-based vaccines. Each vaccine exhibits a different potency and duration of efficacy, as determined by the antigen design, adjuvant molecules, vaccine delivery platforms, and immunization method. In this review, we will introduce a few of the leading non-viral vaccines that are under clinical stage development and discuss delivery strategies to improve vaccine efficacy, duration of protection, safety, and mass vaccination.
. 2020 Dec 16;169:137-151.
doi: 10.1016/j.addr.2020.12.008. Online ahead of print.
Non-viral COVID-19 vaccine delivery systems
Kyung Soo Park[SUP] 1 [/SUP], Xiaoqi Sun[SUP] 2 [/SUP], Marisa E Aikins[SUP] 2 [/SUP], James J Moon[SUP] 3 [/SUP]
Affiliations
- PMID: 33340620
- PMCID: PMC7744276
- DOI: 10.1016/j.addr.2020.12.008
Abstract
The novel corona virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the globe at a formidable speed, causing tens of millions of cases and more than one million deaths in less than a year of its report in December 2019. Since then, companies and research institutions have raced to develop SARS-CoV-2 vaccines, ranging from conventional viral and protein-based vaccines to those that are more cutting edge, including DNA- and mRNA-based vaccines. Each vaccine exhibits a different potency and duration of efficacy, as determined by the antigen design, adjuvant molecules, vaccine delivery platforms, and immunization method. In this review, we will introduce a few of the leading non-viral vaccines that are under clinical stage development and discuss delivery strategies to improve vaccine efficacy, duration of protection, safety, and mass vaccination.